Gene Center Munich
print


Breadcrumb Navigation


Content

Publications

2021   |   2020   |   2019   |   2018   |   2017   |   2016   |   2015   |   2014   |   2013   |   2012   |   2011   |   2010   |   2009   |   2008   |   2007   |   2006   |   2005 and before

 

2021

Immune Biology of Acute Myeloid Leukemia: Implications for Immunotherapy.
Khaldoyanidi S, Nagorsen D, Stein A, Ossenkoppele G, Subklewe M.
J Clin Oncol.
2021 Jan 12:JCO2000475. doi: 10.1200/JCO.20.00475. Review PubMed

A modular and controllable T cell therapy platform for acute myeloid leukemia.
Benmebarek MR, Cadilha BL, Herrmann M, Lesch S, Schmitt S, Stoiber S, Darwich A, Augsberger C, Brauchle B, Rohrbacher L, Oner A, Seifert M, Schwerdtfeger M, Gottschlich A, Rataj F, Fenn NC, Klein C, Subklewe M, Endres S, Hopfner KP, Kobold S.
Leukemia 2021 Jan 7:1-15. doi: 10.1038/s41375-020-01109-w. PubMed

2020

Fusion of Bacterial Flagellin to a Dendritic Cell-Targeting αCD40 Antibody Construct Coupled With Viral or Leukemia-Specific Antigens Enhances Dendritic Cell Maturation and Activates Peptide-Responsive T Cells.
Schmitt S, Tahk S, Lohner A, Hänel G, Maiser A, Hauke M, Patel L, Rothe M, Josenhans C, Leonhardt H, Griffioen M, Deiser K, Fenn NC, Hopfner KP, Subklewe M.
Front Immunol. 2020 Nov 12;11:602802. doi: 10.3389/fimmu.2020.602802. PubMed

CLEC12A and CD33 co-expression as preferential target on pediatric AML for combinatorial immunotherapy.
Willier S, Rothämel P, Hastreiter M, Wilhelm J, Stenger D, Blaeschke F, Rohlfs M, Kaeuferle T, Schmid I, Albert MH, Binder V, Subklewe M, Klein C, Feuchtinger T.
Blood 2020 Oct 22;blood.2020006921. doi: 10.1182/blood.2020006921. PubMed 

Transformation of diffuse large B cell lymphoma into dendritic sarcoma under CAR T cell therapy detected on 18F-FDG PET/CT.
Winkelmann M, Rejeski K, Unterrainer M, Schmidt C, Ruzicka M, Ricke J, Rudelius M, Subklewe M, Kunz WG.
Eur J Nucl Med Mol Imaging 2020 Aug 19. doi: 10.1007/s00259-020-05000-9. PubMed

[COVID-19 from the Perspective of Haematology and Haemostaseology].
Spiekermann K, Subklewe M, Hildebrandt M, Humpe A, von Bergwelt-Baildon M.
Dtsch Med Wochenschr. 2020 Jul;145(15):1044-1050. doi: 10.1055/a-1164-4191. PubMed 

Characterization of a Novel FLT3 BiTE® Antibody Construct for the Treatment of Acute Myeloid Leukemia.
Brauchle B, Goldstein RL, Karbowski CM, Henn A, Li C-M, Bücklein VL, Krupka C, Boyle MC, Koppikar P, Haubner S, Wahl J, Dahlhoff C, Raum T, Rardin MJ, Sastri C, Rock DA, von Bergwelt-Baildon M, Frank B, Metzeler KH, Case R, Friedrich M, Balazs M, Spiekermann K, Coxon A, Subklewe M, Arvedson T.
Mol. Cancer Ther. 2020 Jun 9; doi: 10.1158/1535-7163.MCT-19-1093. PubMed

The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types.
Einsele H, Borghaei H, Orlowski RZ, Subklewe M, Roboz GJ, Zugmaier G, Kufer P, Iskander K, Kantarjian HM.
Cancer 2020 Jul 15;126(14):3192-3201. doi: 10.1002/cncr.32909. Review PubMed

A comparative view on the expression patterns of PD-L1 and PD-1 in soft tissue sarcomas.
Orth MF, Buecklein VL, Kampmann E, Subklewe M, Noessner E, Cidre-Aranaz F, Romero-Pérez L, Wehweck FS, Lindner L, Issels R, Kirchner T, Altendorf-Hofmann A, Grünewald TGP, Knösel T. 
Cancer Immunol Immunother. 2020 Jul;69(7):1353-1362. doi: 10.1007/s00262-020-02552-5. PubMed 

Ten things the hematologist wants you to know about CAR-T cells.
Böll B, Subklewe M, von Bergwelt-Baildon M.
Intensive Care Med. 2020 Jun;46(6):1243-1245. doi: 10.1007/s00134-020-06002-9. doi: 10.1007/s00134-020-06002-9. PubMed 

Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.
Herold T, Rothenberg-Thurley M, Grunwald VV, Janke H, Goerlich D, Sauerland MC, Konstandin NP, Dufour A, Schneider S, Neusser M, Ksienzyk B, Greif PA, Subklewe M, Faldum A, Bohlander SK, Braess J, Wörmann B, Krug U, Berdel WE, Hiddemann W, Spiekermann K, Metzeler KH. 
Leukemia 2020 Mar 30; doi: 10.1038/s41375-020-0806-0. PubMed

Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study.
Montesinos P, Roboz GJ, Bulabois CE, Subklewe M, Platzbecker U, Ofran Y, Papayannidis C, Wierzbowska A, Shin HJ, Doronin V, Deneberg S, Yeh SP, Ozcan MA, Knapper S, Cortes J, Pollyea DA, Ossenkoppele G, Giralt S, Döhner H, Heuser M, Xiu L, Singh I, Huang F, Larsen JS, Wei AH.
Leukemia 2020 Mar 16; doi:10.1038/s41375-020-0773-5. PubMed 

Toll-like receptor 7/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: results of a phase I trial. 
Lichtenegger FS, Schnorfeil FM, Rothe M, Deiser K, Altmann T, Bücklein VL, Köhnke T, Augsberger C, Konstandin NP, Spiekermann K, Moosmann A, Boehm S, Boxberg M, Heemskerk MH, Goerlich D, Wittmann G, Wagner B, Hiddemann W, Schendel DJ, Kvalheim G, Bigalke I, Subklewe M.
Clin Transl Immunology. 2020 Mar 3;9(3):e1117. doi: 10.1002/cti2.1117. PubMed

2019

RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade.
Ruzicka M, Koenig LM, Formisano S, Boehmer DFR, Vick B, Heuer EM, Meinl H, Kocheise L, Zeitlhöfler M, Ahlfeld J, Kobold S, Endres S, Subklewe M, Duewell P, Schnurr M, Jeremias I, Lichtenegger FS, Rothenfusser S.
Leukemia 2019 Nov 18;8(5). doi: 10.1038/s41375-019-0639-x. PubMed

Determinants of response and resistance to CAR T cell therapy.
Lesch S, Benmebarek MR, Cadilha BL, Stoiber S, Subklewe M, Endres S, Kobold S.
Semin Cancer Biol. 2019 Nov 6; pii: S1044-579X(19)30219-6. doi: 10.1016/j.semcancer.2019.11.004. Review PubMed 

Patients with spontaneous remission of high-risk MDS and AML show persistent preleukemic clonal hematopoiesis.
Grunwald VV, Hentrich M, Schiel X, Dufour A, Schneider S, Neusser M, Subklewe M, Fiegl M, Hiddemann W, Spiekermann K, Rothenberg-Thurley M, Metzeler KH.
Blood Adv. 2019 Sep 24;3(18):2696-2699. doi: 10.1182/bloodadvances.2019000265. PubMed 

Chimeric Antigen Receptor T Cells: A Race to Revolutionize Cancer Therapy.
Subklewe M, von Bergwelt-Baildon M, Humpe A.
Transfus Med Hemother. 2019 Feb;46(1):15-24. doi: 10.1159/000496870. Review PubMed

Advances in cancer immunotherapy 2019 - latest trends.
Kruger S, Ilmer M, Kobold S, Cadilha BL, Endres S, Ormanns S, Schuebbe G, Renz BW, D'Haese JG, Schloesser H, Heinemann V, Subklewe M, Boeck S, Werner J, von Bergwelt-Baildon M.
J Exp Clin Cancer Res. 2019 Jun 19;38(1):268. doi: 10.1186/s13046-019-1266-0. Review PubMed

Dendritic Cell-Based Immunotherapy of Acute Myeloid Leukemia.
Van Acker HH, Versteven M, Lichtenegger FS, Roex G, Campillo-Davo D, Lion E, Subklewe M, Van Tendeloo VF, Berneman ZN, Anguille S.
J Clin Med. 2019 Apr 27;8(5). pii: E579. doi: 10.3390/jcm8050579. Review. PubMed

Response assessment in acute myeloid leukemia by flow cytometry supersedes cytomorphology at time of aplasia, amends cases without molecular residual disease marker and serves as an independent prognostic marker at time of aplasia and post-induction.
Köhnke T, Bücklein V, Rechkemmer S, Schneider S, Rothenberg-Thurley M, Metzeler KH, Sauerland MC, Hiddemann W, Spiekermann K, Subklewe M.
Haematologica. 2019 Apr 4. pii: haematol.2018.215236. doi: 10.3324/haematol.2018.215236. PubMed

Abundant GAD-reactive B cells in GAD-antibody-associated neurological disorders.
Thaler FS, Thaller AL, Biljecki M, Schuh E, Winklmeier S, Mahler CF, Gerhards R, Völk S, Schnorfeil F, Subklewe M, Hohlfeld R, Kümpfel T, Meinl E.
Ann Neurol. 2019 Jan 11. doi: 10.1002/ana.25414. PubMed

top

2018

Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study.
Braess J, Amler S, Kreuzer KA, Spiekermann K, Lindemann HW, Lengfelder E, Graeven U, Staib P, Ludwig WD, Biersack H, Ko YD, Uppenkamp MJ, De Wit M, Korsten S, Peceny R, Gaska T, Schiel X, Behringer DM, Kiehl MG, Zinngrebe B, Meckenstock G, Roemer E, Medgenberg D, Spaeth-Schwalbe E, Massenkeil G, Hindahl H, Schwerdtfeger R, Trenn G, Sauerland C, Koch R, Lablans M, Faldum A, Görlich D, Bohlander SK, Schneider S, Dufour A, Buske C, Fiegl M, Subklewe M, Braess B, Unterhalt M, Baumgartner A, Wörmann B, Beelen D, Hiddemann W; AML-CG.
Leukemia. 2018 Oct 1. doi: 10.1038/s41375-018-0268-9. PubMed

Bifunctional PD-1 x αCD3 x αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia.
Herrmann M, Krupka C, Deiser K, Brauchle B, Marcinek A, Ogrinc Wagner A, Rataj F, Mocikat R, Metzeler KH, Spiekermann K, Kobold S, Fenn NC, Hopfner KP, Subklewe M.
Blood. 2018 Oct 1. doi: 10.1182/blood-2018-05-849802. PubMed

Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells.
Braciak TA, Roskopf CC, Wildenhain S, Fenn NC, Schiller CB, Schubert IA, Jacob U, Honegger A, Krupka C, Subklewe M, Spiekermann K, Hopfner KP, Fey GH, Aigner M, Krause S, Mackensen A, Oduncu FS.
Oncoimmunology. 2018 Jul 30;7(9):e1472195. doi: 10.1080/2162402X.2018.1472195. PubMed

[Challenges in Immuno-Oncology - Possibilities for Optimization].
Shimabukuro-Vornhagen A, Subklewe M, von Bergwelt-Baildon M.
Dtsch Med Wochenschr. 2018 Jul;143(14):1022-1029. doi: 10.1055/a-0549-6987. German. PubMed

Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML.
Haubner S, Perna F, Köhnke T, Schmidt C, Berman S, Augsberger C, Schnorfeil FM, Krupka C, Lichtenegger FS, Liu X, Kerbs P, Schneider S, Metzeler KH, Spiekermann K, Hiddemann W, Greif PA, Herold T, Sadelain M, Subklewe M.
Leukemia. 2018 Jun 26. doi: 10.1038/s41375-018-0180-3. PubMed

Cytokine release syndrome.
Shimabukuro-Vornhagen A, Gödel P, Subklewe M, Stemmler HJ, Schlößer HA, Schlaak M, Kochanek M, Böll B, von Bergwelt-Baildon MS.
J Immunother Cancer. 2018 Jun 15;6(1):56. doi: 10.1186/s40425-018-0343-9. Review. PubMed

Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged ≥ 75 years.
Prassek VV, Rothenberg-Thurley M, Sauerland MC, Herold T, Janke H, Ksienzyk B, Konstandin NP, Goerlich D, Krug U, Faldum A, Berdel WE, Wörmann B, Braess J, Schneider S, Subklewe M, Bohlander SK, Hiddemann W, Spiekermann K, Metzeler KH.
Haematologica. 2018 Jun 14. doi: 10.3324/haematol.2018.191536. PubMed

Immunosuppression is associated with clinical features and relapse risk of B cell posttransplant lymphoproliferative disorder: A retrospective analysis based on the prospective, international, multicenter PTLD-1 trials.
Zimmermann H, Babel N, Dierickx D, Morschhauser F, Mollee P, Zaucha JM, Dreyling MH, Dührsen U, Reinke P, Verhoef G, Subklewe M, Hüttmann A, Tousseyn T, Bachy E, Hauser IA, Tarella C, Van Den Neste E, Gheysens O, Anagnostopoulos I, Leblond V, Riess H, Choquet S, Trappe RU.
Transplantation. 2018 May 11. doi: 10.1097/TP.0000000000002269. PubMed

Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells.
Lichtenegger FS, Rothe M, Schnorfeil FM, Deiser K, Krupka C, Augsberger C, Schlüter M, Neitz J, Subklewe M.
Front Immunol. 2018 Feb 27;9:385. doi: 10.3389/fimmu.2018.00385. PubMed

top

2017

Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.
Rothenberg-Thurley M, Amler S, Goerlich D, Köhnke T, Konstandin NP, Schneider S, Sauerland MC, Herold T, Hubmann M, Ksienzyk B, Zellmeier E, Bohlander SK, Subklewe M, Faldum A, Hiddemann W, Braess J, Spiekermann K, Metzeler KH.
Leukemia. 2017 Dec 18. doi: 10.1038/leu.2017.350. PubMed

A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia.
Herold T, Jurinovic V, Batcha AMN, Bamopoulos SA, Rothenberg-Thurley M, Ksienzyk B, Hartmann L, Greif PA, Phillippou-Massier J, Krebs S, Blum H, Amler S, Schneider S, Konstandin N, Sauerland MC, Görlich D, Berdel WE, Wörmann BJ, Tischer J, Subklewe M, Bohlander SK, Braess J, Hiddemann W, Metzeler KH, Mansmann U, Spiekermann K.
Haematologica. 2017 Dec 14. pii: haematol.2017.178442. doi: 10.3324/haematol.2017.178442. PubMed

End-of-treatment positron emission tomography after uniform first-line therapy of B cell posttransplant lymphoproliferative disorder identifies patients at low risk of relapse in the prospective German PTLD registry.
Zimmermann H, Denecke T, Dreyling MH, Franzius C, Reinke P, Subklewe M, Amthauer H, Kneba M, Riess H, Trappe RU.
Transplantation. 2017 Nov 17. doi: 10.1097/TP.0000000000002006. PubMed

The DNA Inflammasome in Human Myeloid Cells Is Initiated by a STING-Cell Death Program Upstream of NLRP3.
Gaidt MM, Ebert TS, Chauhan D, Ramshorn K, Pinci F, Zuber S, O'Duill F, Schmid-Burgk JL, Hoss F, Buhmann R, Wittmann G, Latz E, Subklewe M, Hornung V.
Cell. 2017 Nov 16;171(5):1110-1124.e18. doi: 10.1016/j.cell.2017.09.039. PubMed

Diagnosis of CLL revisited: increased specificity by a modified five-marker scoring system including CD200.
Köhnke T, Wittmann VK, Bücklein VL, Lichtenegger F, Pasalic Z, Hiddemann W, Spiekermann K, Subklewe M.
Br J Haematol. 2017 Nov;179(3):480-487. doi: 10.1111/bjh.14901. PubMed

Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia.
Reiter K, Polzer H, Krupka C, Maiser A, Vick B, Rothenberg-Thurley M, Metzeler KH, Dörfel D, Salih HR, Jung G, Nößner E, Jeremias I, Hiddemann W, Leonhardt H, Spiekermann K, Subklewe M, Greif PA.
Leukemia. 2017 Aug 14. doi: 10.1038/leu.2017.257. PubMed

A fluorescence in situ hybridization-based screen allows rapid detection of adverse cytogenetic alterations in patients with acute myeloid leukemia.
Sandhöfer N, Metzeler KH, Kakadia PM, Pasalic Z, Hiddemann W, Neusser M, Steinlein O, Fiegl M, Subklewe M, Spiekermann K, Bohlander SK, Schneider S, Braess J. 
Genes Chromosomes Cancer. 2017 Aug;56(8):632-638. doi: 10.1002/gcc.22466. PubMed

Recent developments in immunotherapy of acute myeloid leukemia.
Lichtenegger FS, Krupka C, Haubner S, Köhnke T, Subklewe M.
J Hematol Oncol. 2017 Jul 25;10(1):142. doi: 10.1186/s13045-017-0505-0. Review. PubMed

Targeting CD157 in AML using a novel, Fc-engineered antibody construct.
Krupka C, Lichtenegger FS, Köhnke T, Bögeholz J, Bücklein V, Roiss M, Altmann T, Do TU, Dusek R, Wilson K, Bisht A, Terrett J, Aud D, Pombo-Villar E, Rohlff C, Hiddemann W, Subklewe M.
Oncotarget. 2017 May 30;8(22):35707-35717. doi: 10.18632/oncotarget.16060. PubMed

SIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells.
Ponce LP, Fenn NC, Moritz N, Krupka C, Kozik JH, Lauber K, Subklewe M, Hopfner KP.
Oncotarget. 2017 Feb 14;8(7):11284-11301. doi: 10.18632/oncotarget.14500. PubMed

Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.
Trappe RU, Dierickx D, Zimmermann H, Morschhauser F, Mollee P, Zaucha JM, Dreyling MH, Döhrsen U, Reinke P, Verhoef G, Subklewe M, Hüttmann A, Tousseyn T, Salles G, Kliem V, Hauser IA, Tarella C, Van Den Neste E, Gheysens O, Anagnostopoulos I, Leblond V, Riess H, et al.
J Clin Oncol. 2017 Feb 10;35(5):536-543. doi: 10.1200/JCO.2016.69.3564 PubMed

top

2016

Features of Human CD3+CD20+ T Cells.
Schuh E, Berer K, Mulazzani M, Feil K, Meinl I, Lahm H, Krane M, Lange R, Pfannes K, Subklewe M, Gürkov R, Bradl M, Hohlfeld R, Kümpfel T, Meinl E, Krumbholz M.
J Immunol
. 2016 Aug 15;197(4):1111-7. doi: 10.4049/jimmunol.1600089. PubMed

Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.
Metzeler KH, Herold T, Rothenberg-Thurley M, Amler S, Sauerland MC, Görlich D, Schneider S, Konstandin NP, Dufour A, Bräundl K, Ksienzyk B, Zellmeier E, Hartmann L, Greif PA, Fiegl M, Subklewe M, Bohlander SK, Krug U, Faldum A, Berdel WE, Wörmann B, Büchner T, et al.
Blood. 2016 Aug 4;128(5):686-98. doi: 10.1182/blood-2016-01-693879. PubMed

Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia.
Herhaus P, Habringer S, Philipp-Abbrederis K, Vag T, Gerngross C, Schottelius M, Slotta-Huspenina J, Steiger K, Altmann T, Weißer T, Steidle S, Schick M, Jacobs L, Slawska J, Müller-Thomas C, Verbeek M, Subklewe M, Peschel C, Wester HJ, Schwaiger M, Götze K, Keller U.
Haematologica. 2016 Aug;101(8):932-40. doi: 10.3324/haematol.2016.142976. PubMed 

Progressive natural killer cell dysfunction associated with alterations in subset proportions and receptor expression in soft-tissue sarcoma patients.
Böcklein V, Adunka T, Mendler AN, Issels R, Subklewe M, Schmollinger JC, Noessner E.
Oncoimmunology. 2016 Apr 29;5(7):e1178421. doi: 10.1080/2162402X.2016.1178421. PubMed

Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism. Krupka C, Kufer P, Kischel R, Zugmaier G, Lichtenegger FS, Köhnke T, Vick B, Jeremias I, Metzeler KH, Altmann T, Schneider S, Fiegl M, Spiekermann K, Bauerle PA, Hiddemann W, Riethmüller G, Subklewe M.
Leukemia. 2016 Feb;30(2):484-91. doi: 10.1038/leu.2015.214. PubMed

top

2015

RNA and protein expression of herpesvirus entry mediator (HVEM) is associated with molecular markers, immunity-related pathways and relapse-free survival of patients with AML.
Lichtenegger FS, Kondla I, Krempasky M, Weber AL, Herold T, Krupka C, Spiekermann K, Schneider S, Büchner T, Berdel WE, Wörmann BJ, Hiddemann W, Subklewe M.
Cancer Immunol Immunother. 2015 Dec;64(12):1505-15. doi: 10.1007/s00262-015-1755-8. PubMed

Immunotherapy in Tumors.
Kobold S, Duewell P, Schnurr M, Subklewe M, Rothenfusser S, Endres S.
Dtsch Arztebl Int. 2015 Nov 27;112(48):809-15. doi: 10.3238/arztebl.2015.0809. Review. PubMed 

Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab.
Köhnke T, Krupka C, Tischer J, Knösel T, Subklewe M.
J Hematol Oncol. 2015 Oct 8;8:111. doi: 10.1186/s13045-015-0213-6. PubMed

Clinical overview of anti-CD19 BiTE(®) and ex vivo data from anti-CD33 BiTE(®) as examples for retargeting T cells in hematologic malignancies.
Zugmaier G, Klinger M, Schmidt M, Subklewe M.
Mol Immunol. 2015 Oct;67(2 Pt A):58-66. doi: 10.1016/j.molimm.2015.02.033. Review. PubMed

T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment.
Schnorfeil FM, Lichtenegger FS, Emmerig K, Schlueter M, Neitz JS, Draenert R, Hiddemann W, Subklewe M.
J Hematol Oncol. 2015 Jul 30;8:93. doi: 10.1186/s13045-015-0189-2. PubMed

Immunotherapy for Acute Myeloid Leukemia. Lichtenegger FS, Krupka C, Köhnke T, Subklewe M.
Semin Hematol. 2015 Jul;52(3):207-14. doi: 10.1053/j.seminhematol.2015.03.006. Review. PubMed

Bendamustine and the immune system: a wolf in sheep's clothing?
Dreyling M, Subklewe M.
Leuk Lymphoma. 2015 Apr;56(4):837-8. doi: 10.3109/10428194.2015.1024942. PubMed

Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia.
Sandhöfer N, Metzeler KH, Rothenberg M, Herold T, Tiedt S, Groiß V, Carlet M, Walter G, Hinrichsen T, Wachter O, Grunert M, Schneider S, Subklewe M, Dufour A, Frühling S, Klein HG, Hiddemann W, Jeremias I, Spiekermann K.
Leukemia. 2015 Apr;29(4):828-38. doi: 10.1038/leu.2014.305. PubMed

An advanced preclinical mouse model for acute myeloid leukemia using patients' cells of various genetic subgroups and in vivo bioluminescence imaging.
Vick B, Rothenberg M, Sandhöfer N, Carlet M, Finkenzeller C, Krupka C, Grunert M, Trumpp A, Corbacioglu S, Ebinger M, André MC, Hiddemann W, Schneider S, Subklewe M, Metzeler KH, Spiekermann K, Jeremias I.
PLoS One. 2015 Mar 20;10(3):e0120925. doi: 10.1371/journal.pone.0120925. PubMed

Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse.
Köhnke T, Sauter D, Ringel K, Hoster E, Laubender RP, Hubmann M, Bohlander SK, Kakadia PM, Schneider S, Dufour A, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Braess J, Hiddemann W, Spiekermann K, Subklewe M.
Leukemia. 2015 Feb;29(2):377-86. doi: 10.1038/leu.2014.186. PubMed

top

2014

New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia.
Subklewe M, Geiger C, Lichtenegger FS, Javorovic M, Kvalheim G, Schendel DJ, Bigalke I.
Cancer Immunol Immunother. 2014 Oct;63(10):1093-103. doi: 10.1007/s00262-014-1600-5. Review. PubMed

Impaired NK cells and increased T regulatory cell numbers during cytotoxic maintenance therapy in AML.
Lichtenegger FS, Lorenz R, Gellhaus K, Hiddemann W, Beck B, Subklewe M.
Leuk Res. 2014 Aug;38(8):964-9. doi: 10.1016/j.leukres.2014.05.014. PubMed

Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse.
Hubmann M, Köhnke T, Hoster E, Schneider S, Dufour A, Zellmeier E, Fiegl M, Braess J, Bohlander SK, Subklewe M, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Hiddemann W, Spiekermann K.
Haematologica. 2014 Aug;99(8):1317-25. doi: 10.3324/haematol.2014.104133. PubMed

Combination of Complement-Dependent Cytotoxicity and Relative Fluorescent Quantification of HLA Length Polymorphisms Facilitates the Detection of a Loss of Heterozygosity.
Witter K, Reibke R, Subklewe M, Zahn R, Kauke T, Spiekermann K, Spannagl M, Tischer J, Hiddemann W, Dick A.
Bone Marrow Res. 2014;2014:541345. doi: 10.1155/2014/541345. PubMed

Discovery of highly potent p53-MDM2 antagonists and structural basis for anti-acute myeloid leukemia activities.
Huang Y, Wolf S, Beck B, Köhler LM, Khoury K, Popowicz GM, Goda SK, Subklewe M, Twarda A, Holak TA, Dömling A.
ACS Chem Biol
. 2014 Mar 21;9(3):802-11. doi: 10.1021/cb400728e. PubMed

Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia.
Janke H, Pastore F, Schumacher D, Herold T, Hopfner KP, Schneider S, Berdel WE, Büchner T, Woermann BJ, Subklewe M, Bohlander SK, Hiddemann W, Spiekermann K, Polzer H.
PLoS One. 2014 Mar 7;9(3):e89560. doi: 10.1371/journal.pone.0089560. PubMed

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.
Krupka C, Kufer P, Kischel R, Zugmaier G, Bögeholz J, Köhnke T, Lichtenegger FS, Schneider S, Metzeler KH, Fiegl M, Spiekermann K, Baeuerle PA, Hiddemann W, Riethmüller G, Subklewe M.
Blood. 2014 Jan 16;123(3):356-65. doi: 10.1182/blood-2013-08-523548. PubMed

top

2013

Structures of the human and Drosophila 80S ribosome.
Anger AM, Armache JP, Berninghausen O, Habeck M, Subklewe M, Wilson DN, Beckmann R.
Nature. 2013 May 2;497(7447):80-5. doi: 10.1038/nature12104. PubMed

Current strategies in immunotherapy for acute myeloid leukemia.
Lichtenegger FS, Schnorfeil FM, Hiddemann W, Subklewe M.
Immunotherapy. 2013 Jan;5(1):63-78. doi: 10.2217/imt.12.145. Review. PubMed

top

2012

CD86 and IL-12p70 are key players for T helper 1 polarization and natural killer cell activation by Toll-like receptor-induced dendritic cells.
Lichtenegger FS, Mueller K, Otte B, Beck B, Hiddemann W, Schendel DJ, Subklewe M.
PLoS One. 2012;7(9):e44266. doi: 10.1371/journal.pone.0044266. PubMed

Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients.
Dufour A, Schneider F, Hoster E, Benthaus T, Ksienzyk B, Schneider S, Kakadia PM, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Braess J, Subklewe M, Hiddemann W, Bohlander SK, Spiekermann K; AML CG study group..
Ann Hematol
. 2012 Jul;91(7):1051-63. doi: 10.1007/s00277-012-1423-4. PubMed

Advanced systemic mastocytosis as a mimicker of metastatic clear cell renal cell carcinoma.
Walz C, Subklewe M, Horny HP, Flaig M, Reiter A, Kirchner T, Sotlar K.
Leuk Res. 2012 Jun;36(6):799-801. doi: 10.1016/j.leukres.2012.02.031. PubMed

top

2011

Effects of TLR agonists on maturation and function of 3-day dendritic cells from AML patients in complete remission.
Beck B, Dörfel D, Lichtenegger FS, Geiger C, Lindner L, Merk M, Schendel DJ, Subklewe M.
J Transl Med. 2011 Sep 13;9:151. doi: 10.1186/1479-5876-9-151. PubMed

top

2010

[Hematology 2010].
Dreyling M, Subklewe M, Braess J, Spiekermann K.
Dtsch Med Wochenschr. 2010 Jun;135(25-26):1322-5. doi: 10.1055/s-0030-1255163. Review. PubMed

A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas.
Weidmann E, Hess G, Chow KU, Krause SW, Subklewe M, Kruse J, Weisel KC, Soekler M, Kim SZ, Napieralski S, Rech J, Dreyling M, Jäger E, Mitrou PS.
Leuk Lymphoma. 2010 Mar;51(3):447-55. doi: 10.3109/10428190903580402. PubMed

top

2009

Hepatosplenic T-cell lymphoma in a patient with Crohn's disease.
Beigel F, Jürgens M, Tillack C, Subklewe M, Mayr D, Göke B, Brand S, Ochsenkühn T.
Nat Rev Gastroenterol Hepatol. 2009 Jul;6(7):433-6. doi: 10.1038/nrgastro.2009.87. Review. PubMed

top

2008

Epstein-Barr virus-associated B-cell lymphoma secondary to FCD-C therapy in patients with peripheral T-cell lymphoma.
Weisel KC, Weidmann E, Anagnostopoulos I, Kanz L, Pezzutto A, Subklewe M.
Int J Hematol
. 2008 Nov;88(4):434-40. doi: 10.1007/s12185-008-0176-2. PubMed

top

2007

Generation of EBV-specific T cells for adoptive immunotherapy: a novel protocol using formalin-fixed stimulator cells to increase biosafety.
Hammer MH, Brestrich G, Mittenzweig A, Roemhild A, Zwinger S, Subklewe M, Beier C, Kurtz A, Babel N, Volk HD, Reinke P.
J Immunother. 2007 Nov-Dec;30(8):817-24. PubMed

Radiologic and pathologic features of a posttransplantation primary central nervous system lymphoma demonstrating Epstein-Barr virus-positive Hodgkin lymphoma.
Subklewe M, Anagnostopoulos I.
Clin Lymphoma Myeloma. 2007 Sep;7(8):535-7. PubMed

Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib.
Subklewe M
, Sebelin-Wulf K, Beier C, Lietz A, Mathas S, Dörken B, Pezzutto A.
Hum Immunol. 2007 Mar;68(3):147-55. PubMed 

top

2006

Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD.
Sebelin-Wulf K, Nguyen TD, Oertel S, Papp-Vary M, Trappe RU, Schulzki A, Pezzutto A, Riess H, Subklewe M.
Transpl Immunol. 2007 Apr;17(3):203-10. PubMed

Association of human leukocyte antigen haplotypes with posttransplant lymphoproliferative disease after solid organ transplantation.
Subklewe M, Marquis R, Choquet S, Leblond V, Garnier JL, Hetzer R, Swinnen LJ, Oertel S, Papp-Vary M, Gonzalez-Barca E, Hepkema BG, Schoenemann C, May J, Pezzutto A, Riess H.
Transplantation. 2006 Oct 27;82(8):1093-100. PubMed

Impairment of circulating myeloid dendritic cells in immunosuppressed renal/pancreas transplant recipients.
Sebelin K, Schulzki A, Kloetzel PM, Dörken B, Pezzutto A, Subklewe M.
Transplantation. 2006 Sep 27;82(6):779-87. PubMed

Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course.
Oertel S, Trappe RU, Zeidler K, Babel N, Reinke P, Hummel M, Jonas S, Papp-Vary M, Subklewe M, Dörken B, Riess H, Gärtner B.
Ann Hematol. 2006 Jul;85(7):478-84. PubMed

top

2005 and before

Dendritic cells expand Epstein Barr virus specific CD8+ T cell responses more efficiently than EBV transformed B cells.
Subklewe M, Sebelin K, Block A, Meier A, Roukens A, Paludan C, Fonteneau JF, Steinman RM, Münz C.
Hum Immunol. 2005 Sep;66(9):938-49. PubMed

Extramedullary manifestation of a donor-derived acute myeloid leukemia in a liver transplant patient.
Subklewe M, Nagy M, Schoch C, Jenisch S, Siebert R, Gesk S, Neuhaus P, Dörken B, Schmidt CA.
Leukemia
. 2004 Dec;18(12):2050-3. PubMed

Dendritic cells for the induction of EBV immunity.
Subklewe M.
Recent Results Cancer Res. 2002;159:38-43. Review. PubMed

Dendritic cells cross-present latency gene products from Epstein-Barr virus-transformed B cells and expand tumor-reactive CD8(+) killer T cells.
Subklewe M, Paludan C, Tsang ML, Mahnke K, Steinman RM, Münz C.
J Exp Med. 2001 Feb 5;193(3):405-11. PubMed

Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1.
Münz C, Bickham KL, Subklewe M, Tsang ML, Chahroudi A, Kurilla MG, Zhang D, O'Donnell M, Steinman RM.
J Exp Med. 2000 May 15;191(10):1649-60. PubMed 

Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion.
Engelmayer J, Larsson M, Subklewe M, Chahroudi A, Cox WI, Steinman RM, Bhardwaj N.
J Immunol. 1999 Dec 15;163(12):6762-8. PubMed

Presentation of epstein-barr virus latency antigens to CD8(+), interferon-gamma-secreting, T lymphocytes.
Subklewe M, Chahroudi A, Bickham K, Larsson M, Kurilla MG, Bhardwaj N, Steinman RM.
Eur J Immunol. 1999 Dec;29(12):3995-4001. PubMed

Induction of Epstein-Barr virus-specific cytotoxic T-lymphocyte responses using dendritic cells pulsed with EBNA-3A peptides or UV-inactivated, recombinant EBNA-3A vaccinia virus.
Subklewe M, Chahroudi A, Schmaljohn A, Kurilla MG, Bhardwaj N, Steinman RM.
Blood. 1999 Aug 15;94(4):1372-81. PubMed

Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells.
Inaba K, Turley S, Yamaide F, Iyoda T, Mahnke K, Inaba M, Pack M, Subklewe M, Sauter B, Sheff D, Albert M, Bhardwaj N, Mellman I, Steinman RM.
J Exp Med. 1998 Dec 7;188(11):2163-73. PubMed

A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells.
Reddy A, Sapp M, Feldman M, Subklewe M, Bhardwaj N.
Blood. 1997 Nov 1;90(9):3640-6. PubMed

Expression of surface markers on alveolar macrophages from symptomatic patients with HIV infection as detected by flow cytometry.
Wasserman K, Subklewe M, Pothoff G, Banik N, Schell-Frederick E.
Chest. 1994 May;105(5):1324-34. PubMed